scholarly journals Effect of isoflavone soy protein supplementation on endometrial thickness, hyperplasia, and endometrial cancer risk in postmenopausal women

2013 ◽  
Vol 20 (8) ◽  
pp. 840-844 ◽  
Author(s):  
Alexander M. Quaas ◽  
Naoko Kono ◽  
Wendy J. Mack ◽  
Howard N. Hodis ◽  
Juan C. Felix ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Soy Protein ◽  
Endometrial Thickness ◽  
Protein Supplementation ◽  
Endometrial Cancer Risk

scholarly journals Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women

2016 ◽  
Vol 25 (7) ◽  
pp. 1081-1089 ◽  
Author(s):  
Louise A. Brinton ◽  
Britton Trabert ◽  
Garnet L. Anderson ◽  
Roni T. Falk ◽  
Ashley S. Felix ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Estrogen Metabolites ◽  
Endometrial Cancer Risk

scholarly journals Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer

2015 ◽  
Vol 33 (10) ◽  
pp. 1186-1190 ◽  
Author(s):  
Polly A. Newcomb ◽  
Michael N. Passarelli ◽  
Amanda I. Phipps ◽  
Garnet L. Anderson ◽  
Jean Wactawski-Wende ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Treatment Of Osteoporosis ◽  
Endometrial Cancer Risk ◽  
Patients With Cancer ◽  
Oral Bisphosphonate ◽  
Intact Uterus ◽  
The Relationship

Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

scholarly journals Caffeinated Coffee, Decaffeinated Coffee and Endometrial Cancer Risk: A Prospective Cohort Study among US Postmenopausal Women

Nutrients ◽  
2011 ◽  
Vol 3 (11) ◽  
pp. 937-950 ◽  
Author(s):  
Ayush Giri ◽  
Susan R. Sturgeon ◽  
Nicole Luisi ◽  
Elizabeth Bertone-Johnson ◽  
Raji Balasubramanian ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cohort Study ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Endometrial Cancer Risk ◽  
Decaffeinated Coffee ◽  
Caffeinated Coffee

scholarly journals Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case–control study within the B∼FIT cohort

2012 ◽  
Vol 20 (1) ◽  
pp. 151-160 ◽  
Author(s):  
Cher M Dallal ◽  
Louise A Brinton ◽  
Douglas C Bauer ◽  
Diana S M Buist ◽  
Jane A Cauley ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Case Control Study ◽  
Case Control ◽  
Endometrial Cancer Risk ◽  
C Peptide ◽  
Hmw Adiponectin ◽  
Control Study

Endometrial cancer risk is strongly influenced by obesity, but the mechanisms of action remain unclear. Leptin and adiponectin, secreted from adipose tissue, reportedly play a role in such carcinogenic processes as cell proliferation, angiogenesis, and insulin regulation. In this case–control study, nested within the Breast and Bone Follow-up of the Fracture Intervention Trial (n=15 595), we assessed pre-diagnostic serum leptin, total adiponectin, and high-molecular-weight (HMW) adiponectin in relation to endometrial cancer among postmenopausal women. During the 10-year follow-up, 62 incident endometrial cases were identified and matched to 124 controls on age, geographical site, time of fasting blood draw at baseline (1992–1993), and trial participation status. Adipokines and C-peptide were measured by ELISA. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated via conditional logistic regression, with exposures categorized in tertiles (T). Multivariable models considered C-peptide, BMI (kg/m2), and estradiol (E2) as potential confounders. Endometrial cancer risk was significantly associated with higher leptin levels, adjusted for E2 and C-peptide (ORT3 vs T1=2.96; 95% CI, 1.21–7.25; P trend <0.01). After further adjustment for BMI, the estimates were attenuated and the positive trend was no longer statistically significant (ORT3 vs T1=2.11; 95% CI, 0.69–6.44; P trend=0.18). No significant associations were observed with adiponectin or HMW adiponectin and endometrial cancer. Our findings with leptin suggest that the leptin–BMI axis might increase endometrial cancer risk through mechanisms other than estrogen-driven proliferation. Continued exploration of these pathways in larger prospective studies may help elucidate mechanisms underlying observed obesity–endometrial cancer associations.

scholarly journals Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort

2015 ◽  
Vol 138 (5) ◽  
pp. 1129-1138 ◽  
Author(s):  
Mireia Obón-Santacana ◽  
Heinz Freisling ◽  
Petra H. Peeters ◽  
Leila Lujan-Barroso ◽  
Pietro Ferrari ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Case Control Study ◽  
Case Control ◽  
Endometrial Cancer Risk ◽  
Nested Case Control ◽  
Control Study

scholarly journals Plasma Adiponectin Levels and Endometrial Cancer Risk in Pre- and Postmenopausal Women

2007 ◽  
Vol 92 (1) ◽  
pp. 255-263 ◽  
Author(s):  
Anne E. Cust ◽  
Rudolf Kaaks ◽  
Christine Friedenreich ◽  
Fabrice Bonnet ◽  
Martine Laville ◽  
...  
Keyword(s):  
Risk Factors ◽  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Binding Protein ◽  
Inverse Association ◽  
Endometrial Cancer Risk ◽  
Plasma Adiponectin ◽  
Igf Binding ◽  
Igf Binding Protein

Abstract Background: Adiponectin, an adipocytokine secreted by adipose tissue, is decreased in obesity, insulin resistance, type 2 diabetes, and polycystic ovary syndrome, all of which are well-established risk factors for endometrial cancer. Methods: We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition to examine the relation between prediagnostic plasma adiponectin levels and endometrial cancer risk. Among pre- and postmenopausal women who were not currently using exogenous hormones, 284 women developed incident endometrial cancer during an average of 5.1 yr of follow-up. Using risk set sampling, 548 control subjects were selected, matched on center, age, menopausal status, phase of menstrual cycle, time of blood draw, and fasting status. Conditional logistic regression models were used to estimate relative risks and 95% confidence intervals. Results: Adiponectin levels were inversely associated with endometrial cancer risk [body mass index-adjusted relative risk for the top vs. bottom quartile = 0.56 (95% confidence interval 0.36–0.86), Ptrend = 0.006]. There was evidence of a stronger inverse association among obese women than among nonobese women (Pheterogeneity = 0.03). The inverse association also appeared stronger for women who were postmenopausal or perimenopausal than premenopausal at baseline, but this was not statistically significantly heterogeneous (Pheterogeneity = 0.51). The association remained statistically significant after separate adjustment for other obesity-related physiological risk factors such as C-peptide, IGF binding protein-1, IGF binding protein-2, SHBG, estrone, or free testosterone but only marginally statistically significant after simultaneous adjustment for these factors. Conclusions: High circulating adiponectin levels are associated with reduced endometrial cancer risk, largely independent of other obesity-related risk factors.

Sign in / Sign up

Export Citation Format

Share Document